Website

MPLUS (MPL)

ICO

Last updated: Apr 21, 2019

M+plus is a supply chain platform with blockchain method in order to distribute pharmaceuticals and functional foods.

IMPORTANT: By investing in this business you agree to ourDisclaimer. All information including our rating, is provided merely for informational purposes. CryptoTotem does not provide investment advice.

Overview

Project industry	Blockchain Infrastructure
Product type	Marketplace
Whitepaper	Open

What is MPLUS

Blockchain- decentralized method used to distribute medical products and health food
Halal-certified products
One of company's products is "Silk Fibroin." Multi-function nano-level silk fibroin fat absorption product. It is officially permitted by the Malaysian government to be imported.

Details

Pre-sales: Feb 20, 2018 - Apr 02, 2018
Public sales: Apr 02, 2018 - May 17, 2018
Token supply: 1500000000

Legal

Blockchain Platform: Ethereum
Registration country: Malaysia
Registration year: 2005

Office address: A1-09-06, Arcoris Mont Kiara, No.10, Jalan Kiara, 50480 Kuala Lumpur Malaysia

Token info

Ticker: MPL
Type: Utility-token
Token standard: ERC-20
Token price in USD: 1 MPL = 0.038462 USD
Token price in ETH: 1 Token = 0.000100 ETH
Accepted currencies: ETH
Bonus program:
From 20th Feb. 100％ 280 million tokens
From 17th March 80％ 126 million tokens
From 2nd April 70％ 119 million tokens
From 17th April 60％ 112 million tokens
Token distribution:
50% ICO sales
20% Medic Group ownership
10% team ownership
20% Tokens for supply chain development use
Funds allocation:
40% - development of the international distribution platform
20% - Ethernet Reserve
14% - business development dand R&D
8% - Operations
8% - Marketing
5% - Legal affairs
5% - Management cost

MPLUS Roadmap

Q1-Q2 2018

ICO (Presales) begins;
Head office facilities transfer to Malaysia;
Affiliation of major pharmaceutical company in Malaysia;
Establishment of liaison office in Japan (April 9th).

Q3-Q4 2018

Block chain distribution platform development begins;
Halal certified silk fibroin will be determined.

Q1-Q2 2019

Super placenta medicine approval;
Block chain platform internal operations commence;
China, Thailand, Taiwan, South Korea and others join the distribution platform.

Q2-Q3 2019

Japan affiliates with other major pharmaceutical companies by joining the platform;
Product manufacturing acceptance of Halal certification to Japanese companies;
Product distribution to Islamic markets commences.